KORU CEO gets 15,968 shares via RSU vesting

KORU Medical Systems reported that Chief Executive Officer Linda M. Tharby received common shares through equity compensation and had a portion withheld for taxes.

Rhea-AI Filing Summary

KORU Medical Systems reported that Chief Executive Officer Linda M. Tharby received common shares through equity compensation and had a portion withheld for taxes. On March 16, 2026, she acquired 15,968 shares of common stock at no cost upon vesting of restricted stock units. Of these, 5,756 shares were withheld at $4.28 per share to satisfy tax obligations related to the vesting. After these transactions, she directly holds 10,212 shares of KORU Medical Systems common stock. These events reflect routine compensation-related activity rather than open-market buying or selling.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Tharby Linda M

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Common Stock	15,968	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	5,756	$4.28	$25K

Holdings After Transaction: Common Stock — 10,212 shares (Direct)

Footnotes (2)

1. F1. Represents common stock issued upon vesting of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock upon vesting.
2. F2. Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KORU Medical Systems (KRMD) report for its CEO?

KORU Medical Systems reported that CEO Linda M. Tharby received 15,968 common shares upon vesting of restricted stock units. A portion of these shares was then withheld to cover tax obligations tied to the vesting event.

How many KRMD shares did CEO Linda Tharby receive and how many were withheld?

Linda Tharby received 15,968 KORU Medical Systems common shares upon RSU vesting. Of those, 5,756 shares were withheld to satisfy tax obligations, leaving her with a direct holding of 10,212 shares after the transactions.

Was the KRMD Form 4 transaction an open-market buy or sell?

The KRMD Form 4 shows compensation-related activity, not an open-market trade. Shares were issued upon restricted stock unit vesting, and some were withheld to pay taxes, so no discretionary market purchase or sale occurred.

What price was used for the KRMD shares withheld for CEO tax obligations?

The 5,756 KRMD shares withheld for CEO Linda Tharby’s tax obligations were valued at $4.28 per share. This value was used solely for the tax-withholding calculation related to the restricted stock unit vesting.

How many KRMD shares does the CEO hold after this Form 4 transaction?

Following the vesting and tax withholding, CEO Linda Tharby directly holds 10,212 KORU Medical Systems common shares. This figure reflects her position after receiving 15,968 shares and having 5,756 shares withheld for tax purposes.

What do the restricted stock unit vesting details mean for KRMD shareholders?

The restricted stock unit vesting for KRMD’s CEO represents routine equity compensation. Shares were issued as part of her pay package, with some withheld for taxes, so it does not indicate a new strategic decision to buy or sell shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tharby Linda M

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NEW JERSEY 07430

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		M		15,968	A	$0(1)	15,968	D
Common Stock	03/16/2026		F(2)		5,756	D	$4.28	10,212	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents common stock issued upon vesting of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock upon vesting.

2. Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units.

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams - Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)